More regular updates and key information, updates and news can be found through our tweets
Latest tweets from @CellCentric
FDA and International Myeloma Society mtg: Instead of prior lines of therapy, it’s useful to assess patients by drug class refractory state.
There is a growing population in multiple myeloma that can benefit from therapeutic options that can be delivered in an outpatient community setting.
We continue to advance our pioneering oral p300/CBP inhibitor in Phase II. Inobrodib gets to the heart of progressing multiple myeloma by impacting MYC and IRF4.